Article Details

ImmunityBio Receives FDA RMAT Designation for ANKTIVA and CAR-NK (PD-L1 t-haNK) to ...

Retrieved on: 2025-03-05 17:37:16

Tags for this article:

Click the tags to see associated articles and topics

ImmunityBio Receives FDA RMAT Designation for ANKTIVA and CAR-NK (PD-L1 t-haNK) to .... View article details on hiswai:

Summary

The article discusses ImmunityBio's FDA recognition of their innovative treatments reversing lymphopenia in cancer patients. Tags relate to the article’s focus on cancer treatments and pharmaceutical developments, highlighting advancements in regenerative medicine and immunotherapy by ImmunityBio and Patrick Soon-Shiong.

Article found on: www.latimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up